These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26171487)

  • 21. Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.
    Narasimhan S; Lohoff FW
    Pharmacogenomics; 2012 Mar; 13(4):441-64. PubMed ID: 22380000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mechanism of action of antidepressants and therapeutic perspectives].
    Bourin M; David DJ; Jolliet P; Gardier A
    Therapie; 2002; 57(4):385-96. PubMed ID: 12422559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The serotonin transporter and depression.
    Owens MJ; Nemeroff CB
    Depress Anxiety; 1998; 8 Suppl 1():5-12. PubMed ID: 9809208
    [No Abstract]   [Full Text] [Related]  

  • 24. Glucocorticoids as predictors of treatment response in depression.
    Horstmann S; Binder EB
    Harv Rev Psychiatry; 2011; 19(3):125-43. PubMed ID: 21631159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The development of our understanding of the mechanism of action of antidepressant drugs.
    Vetulani J
    Pol J Pharmacol Pharm; 1991; 43(4):323-38. PubMed ID: 1811223
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacogenetic studies of depression.
    Henn FA
    Biol Psychiatry; 2008 Jun; 63(12):1101-2. PubMed ID: 18514642
    [No Abstract]   [Full Text] [Related]  

  • 27. [Critical view of biochemical factors in depressive syndromes and the prescription of antidepressants].
    Loo H; Zarifian E
    Ann Med Psychol (Paris); 1982 Feb; 140(2):240-51. PubMed ID: 6180668
    [No Abstract]   [Full Text] [Related]  

  • 28. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New approaches to antidepressant drug discovery: beyond monoamines.
    Berton O; Nestler EJ
    Nat Rev Neurosci; 2006 Feb; 7(2):137-51. PubMed ID: 16429123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antidepressant effects of insulin in streptozotocin induced diabetic mice: Modulation of brain serotonin system.
    Gupta D; Kurhe Y; Radhakrishnan M
    Physiol Behav; 2014 Apr; 129():73-8. PubMed ID: 24582678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5HT3 receptors: Target for new antidepressant drugs.
    Gupta D; Prabhakar V; Radhakrishnan M
    Neurosci Biobehav Rev; 2016 May; 64():311-25. PubMed ID: 26976353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression.
    Jann MW; Cohen LJ
    Drug Metabol Drug Interact; 2000; 16(1):39-67. PubMed ID: 10820582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of antidepressant drugs on the hypothalamic-pituitary-adrenal axis activity and glucocorticoid receptor function.
    Budziszewska B
    Pol J Pharmacol; 2002; 54(4):343-9. PubMed ID: 12523487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of gene polymorphisms on depression and its treatment.
    Moret C
    IDrugs; 2004 Jun; 7(6):558-62. PubMed ID: 15197660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential use of histone deacetylase inhibitors in the treatment of depression.
    Fuchikami M; Yamamoto S; Morinobu S; Okada S; Yamawaki Y; Yamawaki S
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():320-4. PubMed ID: 25818247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions.
    Lerer B; Macciardi F
    Int J Neuropsychopharmacol; 2002 Sep; 5(3):255-75. PubMed ID: 12366879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder.
    Weizman S; Gonda X; Dome P; Faludi G
    Neuropsychopharmacol Hung; 2012 Jun; 14(2):87-101. PubMed ID: 22710850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter.
    Müller DJ; Schulze TG; Macciardi F; Ohlraun S; Gross MM; Scherk H; Neidt H; Syagailo YV; Grässle M; Nöthen MM; Maier W; Lesch KP; Rietschel M
    Pharmacopsychiatry; 2002 Jul; 35(4):157-8. PubMed ID: 12163988
    [No Abstract]   [Full Text] [Related]  

  • 39. Convergent animal and human evidence suggests the activin/inhibin pathway to be involved in antidepressant response.
    Ganea K; Menke A; Schmidt MV; Lucae S; Rammes G; Liebl C; Harbich D; Sterlemann V; Storch C; Uhr M; Holsboer F; Binder EB; Sillaber I; Müller MB
    Transl Psychiatry; 2012 Oct; 2(10):e177. PubMed ID: 23092981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Possibility of a pharmacogenetic approach for prediction and personalized medication in major depressive disorder treatment].
    Kato M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):83-92. PubMed ID: 20491282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.